Literature DB >> 6756722

Hidden anti-double stranded DNA antibodies in autoimmune mice.

F Fish, M Ziff.   

Abstract

When MRL/l mouse spleen cell culture supernatants were incubated with normal mouse spleen cells, a two-50-fold increase in anti-dsDNA activity was noted. A smaller increase in anti-ssDNA and no change in anti-TNP antibody activity were observed. This 'hidden' antibody in the MRL/l supernatants could not be revealed by DNAse digestion and could not be absorbed by a DNA cellulose column. Hidden antibody was removed from supernatants by sepharose-anti Ig. After DNAase digestion of the MRL/l supernatants, hidden anti-dsDNA could not be revealed by incubation with spleen cells. All the hidden activity was excluded by gel filtration on Sephacryl S-300 (mol. wt greater than 300,000) but was banded in the low density protein area of caesium chloride equilibrium density gradients. It was also noted that MRL/l mouse sera had hidden anti-dsDNA antibodies. Hidden antibodies were present in both the IgG and IgM classes. The revealed antibodies demonstrated impaired ability to bind Fc specific anti-Ig reagents suggesting that they were partially degraded during the incubation with mouse spleen cells. The hidden anti-dsDNA thus appears to represent a DNA-anti-dsDNA complex, perhaps of very high affinity. It may explain why anti-dsDNA but not anti-ssDNA antibodies are of pathological importance in SLE.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6756722      PMCID: PMC1536706     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Immunology of DNA. V. Analysis of DNA/anti-DNA complexes.

Authors:  L A Aarden; E R De Groot; F Lakmaker
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

2.  Substrate competition between DNase I and anti-DNA antibody.

Authors:  M R Liebling; E V Barnett
Journal:  Clin Immunol Immunopathol       Date:  1977-07

Review 3.  Commentary. Lysosomotropic agents.

Authors:  C de Duve; T de Barsy; B Poole; A Trouet; P Tulkens; F Van Hoof
Journal:  Biochem Pharmacol       Date:  1974-09-15       Impact factor: 5.858

4.  Tumour-bound immunoglobulins. The fate of immunoglobulin disappearing from the surface of coated tumour cells.

Authors:  F Fish; I P Witz; G Klein
Journal:  Clin Exp Immunol       Date:  1974-03       Impact factor: 4.330

5.  The fate of anti-Ig-surface Ig complexes on B lymphocytes.

Authors:  H D Engers; E R Unanue
Journal:  J Immunol       Date:  1973-02       Impact factor: 5.422

6.  A simplified method for cyanogen bromide activation of agarose for affinity chromatography.

Authors:  S C March; I Parikh; P Cuatrecasas
Journal:  Anal Biochem       Date:  1974-07       Impact factor: 3.365

7.  Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus.

Authors:  E M Tan; P H Schur; R I Carr; H G Kunkel
Journal:  J Clin Invest       Date:  1966-11       Impact factor: 14.808

8.  Effect of actinomycin D and puromycin on the in vitro cytotoxic activity of lymphocytes.

Authors:  B D Brondz
Journal:  Transplant Proc       Date:  1969-03       Impact factor: 1.066

9.  Immunoglobulin classes of DNA binding activity in serum and skin in systemic lupus erythematosus.

Authors:  J B Pennebaker; J N Gilliam; M Ziff
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

10.  Immunological studies concerning the nephritis of systemic lupus erythematosus.

Authors:  D Koffler; P H Schur; H G Kunkel
Journal:  J Exp Med       Date:  1967-10-01       Impact factor: 14.307

View more
  2 in total

1.  Nonlinear behaviour of anti-dsDNA antibodies in dilution experiments using ultramicro ELISA.

Authors:  U Wollina
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

2.  Expression in systemic lupus erythematosus of an idiotype common to DNA-binding and nonbinding monoclonal antibodies produced by normal human lymphoid cells.

Authors:  E Cairns; H Massicotte; D A Bell
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.